239 related articles for article (PubMed ID: 35194200)
1. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.
Roux B; Picou F; Debeissat C; Koubi M; Gallay N; Hirsch P; Ravalet N; Béné MC; Maigre M; Hunault M; Mosser J; Etcheverry A; Gyan E; Delhommeau F; Domenech J; Herault O
Cancer Gene Ther; 2022 Aug; 29(8-9):1263-1275. PubMed ID: 35194200
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
[TBL] [Abstract][Full Text] [Related]
4. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
5. Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
Mossner M; Hopfer O; Nowak D; Baldus CD; Neumann U; Kmetsch A; Benlasfer O; John T; Perka C; Thiel E; Hofmann WK
Exp Hematol; 2010 Aug; 38(8):661-5. PubMed ID: 20399247
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
7. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.
Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzén S; Höglund M; Bullinger L; Döhner K; Lehmann S
Epigenetics; 2014 Aug; 9(8):1108-19. PubMed ID: 24866170
[TBL] [Abstract][Full Text] [Related]
8. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
[TBL] [Abstract][Full Text] [Related]
9. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.
Qu X; Davison J; Du L; Storer B; Stirewalt DL; Heimfeld S; Estey E; Appelbaum FR; Fang M
Epigenetics; 2015; 10(6):526-35. PubMed ID: 25996682
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
13. Age-related epigenetic drift in the pathogenesis of MDS and AML.
Maegawa S; Gough SM; Watanabe-Okochi N; Lu Y; Zhang N; Castoro RJ; Estecio MR; Jelinek J; Liang S; Kitamura T; Aplan PD; Issa JP
Genome Res; 2014 Apr; 24(4):580-91. PubMed ID: 24414704
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
15. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Figueroa ME; Skrabanek L; Li Y; Jiemjit A; Fandy TE; Paietta E; Fernandez H; Tallman MS; Greally JM; Carraway H; Licht JD; Gore SD; Melnick A
Blood; 2009 Oct; 114(16):3448-58. PubMed ID: 19652201
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support.
Azadniv M; Myers JR; McMurray HR; Guo N; Rock P; Coppage ML; Ashton J; Becker MW; Calvi LM; Liesveld JL
Leukemia; 2020 Feb; 34(2):391-403. PubMed ID: 31492897
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Huang JC; Basu SK; Zhao X; Chien S; Fang M; Oehler VG; Appelbaum FR; Becker PS
Blood Cancer J; 2015 Apr; 5(4):e302. PubMed ID: 25860293
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
